ReviewPPAR research2016
PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs.
Review in PPAR research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Molecular Iodine/Cells · 2026Article
- Alleviating Mechanism of Microencapsulated Compound Probiotics Against Obesity via PPAR Metabolic Pathway.Probiotics and antimicrobial proteins · 2026Article
- The role of metformin in extracellular matrix-based three-dimensional cell culture Models: A mini-review on therapeutic potentials.Biochemistry and biophysics reports · 2026Review
- Molecular Iodine Exhibited Differential Antiproliferative Actions in Progenitor and Stem Populations from Chemoresistant Cancer Cells.International journal of molecular sciences · 2025Article
- Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors.Frontiers in immunology · 2025Review
- Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies.Cancer medicine · 2024Article
- Exercise and tumor proteome: insights from a neuroblastoma model.Physiological genomics · 2024Article
- Cellular metabolism regulates the differentiation and function of T-cell subsets.Cellular & molecular immunology · 2024Review
- Long non-coding RNA (LncRNA) and epigenetic factors: their role in regulating the adipocytes in bovine.Frontiers in genetics · 2024Review
- Induction ofJournal of clinical biochemistry and nutrition · 2023Article
- Brown adipocytes promote epithelial mesenchymal transition of neuroblastoma cells by inducing PPAR-γ/UCP2 expression.Adipocyte · 2022Article
- Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.Nature communications · 2022Article
- Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models.International journal of molecular sciences · 2021Article
- Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.International journal of molecular sciences · 2021Article
- Peroxisome proliferator-activated receptor gamma in white and brown adipocyte regulation and differentiation.Physiological research · 2020Review
- Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity.Frontiers in oncology · 2019Review
- Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability.Frontiers in pharmacology · 2018Article
- Gene expression and molecular pathway activation signatures ofOncotarget · 2017Article
- Androgen Receptor Regulates the Growth of Neuroblastoma CellsFrontiers in neuroscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.